波士顿 - 市值22.8亿美元的临床阶段制药公司Centessa Pharmaceuticals plc (NASDAQ:CNTA)宣布任命Stephen Kanes医学博士为新任首席医疗官。Kanes博士是一位在神经科学、临床精神病学和药物开发方面拥有30多年经验的神经精神病学专家。他加入Centessa之际，公司正在推进其催眠素受体2 (OX2R)激动剂组合的开发，预计今年将达成多个临床里程碑 ...

Research analysts at TD Cowen initiated coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) in a report issued on Tuesday, Marketbeat Ratings reports. The firm set a “buy” ...

Centessa is rapidly advancing a potential best-in-class and first-in-class portfolio of orexin receptor 2 (OX2R) agonists with a robust series of clinical milestones anticipated this year,” said ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Fintel reports that on January 7, 2025, TD Cowen initiated coverage of Centessa Pharmaceuticals plc - Depositary Receipt () ...

周二，研究公司Cowen开始对Centessa Pharmaceuticals (NASDAQ:CNTA)股票进行覆盖，给予该公司买入评级。这一决定得到了Centessa药物候选ORX750潜力的支撑，该药物正在开发用于治疗过度日间嗜睡。

The last time I wrote about Centessa Pharmaceuticals plc (NASDAQ:CNTA), it was in a Seeking Alpha article entitled “Centessa: ...

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report)’s share price dropped 3.2% on Tuesday . The stock traded as low ...

We recently published an article entitled Why These 10 Stocks Jumped Yesterday. In this article, we are going to take a look ...

Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily developing its lead orexin agonist, ORX-750. ORX-750 targets narcolepsy ...

Current share price of US$16.75 suggests Centessa Pharmaceuticals is potentially 30% undervalued ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...